Investigational Drug Information for Laquinimod
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Laquinimod?
Laquinimod is an investigational drug.
There have been 16 clinical trials for Laquinimod.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 13th 2007.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Teva Pharmaceutical Industries, Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceutical Industries, Ltd.
Summary for Laquinimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,694 |
| WIPO Patent Applications | 563 |
| Japanese Patent Applications | 302 |
| Clinical Trial Progress | Phase 3 (2007-11-13) |
| Vendors | 100 |
Recent Clinical Trials for Laquinimod
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Laquinimod Eye-drops in Healthy Participants | Active Biotech AB | Phase 1 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo | Teva Pharmaceutical Industries | Phase 2 |
Clinical Trial Summary for Laquinimod
Top disease conditions for Laquinimod
Top clinical trial sponsors for Laquinimod
US Patents for Laquinimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
